EquitySector - HealthcareVery High Risk
NAV (21-Nov-24)
Returns (Since Inception)
Fund Size
₹150 Cr
Expense Ratio
0.15%
ISIN
INF109KC1Q72
Minimum SIP
-
Exit Load
-
Inception Date
18 May 2021
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+37.28%
+41.83% (Cat Avg.)
3 Years
+17.50%
+18.69% (Cat Avg.)
Since Inception
+16.26%
— (Cat Avg.)
Equity | ₹150.14 Cr | 100.00% |
Others | ₹0.01 Cr | 0.00% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹33.41 Cr | 22.25% |
Cipla Ltd | Equity | ₹14.27 Cr | 9.51% |
Dr Reddy's Laboratories Ltd | Equity | ₹13.01 Cr | 8.66% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹12.64 Cr | 8.42% |
Divi's Laboratories Ltd | Equity | ₹12.51 Cr | 8.34% |
Apollo Hospitals Enterprise Ltd | Equity | ₹11.9 Cr | 7.93% |
Lupin Ltd | Equity | ₹8.82 Cr | 5.87% |
Aurobindo Pharma Ltd | Equity | ₹6.53 Cr | 4.35% |
Alkem Laboratories Ltd | Equity | ₹5.05 Cr | 3.36% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.95 Cr | 3.30% |
Glenmark Pharmaceuticals Ltd | Equity | ₹4.27 Cr | 2.84% |
Zydus Lifesciences Ltd | Equity | ₹4.19 Cr | 2.79% |
Ipca Laboratories Ltd | Equity | ₹3.61 Cr | 2.40% |
Laurus Labs Ltd | Equity | ₹3.23 Cr | 2.15% |
Syngene International Ltd | Equity | ₹2.6 Cr | 1.73% |
Abbott India Ltd | Equity | ₹2.53 Cr | 1.68% |
Biocon Ltd | Equity | ₹2.38 Cr | 1.58% |
Dr. Lal PathLabs Ltd | Equity | ₹1.92 Cr | 1.28% |
Granules India Ltd | Equity | ₹1.38 Cr | 0.92% |
Metropolis Healthcare Ltd | Equity | ₹0.93 Cr | 0.62% |
Treps | Cash - Repurchase Agreement | ₹0.01 Cr | 0.01% |
Net Current Assets | Cash | ₹-0.01 Cr | 0.00% |
Large Cap Stocks
62.77%
Mid Cap Stocks
32.26%
Small Cap Stocks
4.97%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹150.14 Cr | 100.00% |
Standard Deviation
This fund
16.15%
Cat. avg.
15.67%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
ISIN INF109KC1Q72 | Expense Ratio 0.15% | Exit Load - | Fund Size ₹150 Cr | Age 3 years 6 months | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark NIFTY Healthcare TR TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | 43.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | 37.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | 35.4% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | 37.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | 45.8% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | 43.1% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | 38.2% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | 36.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | 36.6% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | 37.0% |
Total AUM
₹8,99,267 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk